Merck & Company (MRK) 55.88 $MRK
Merck Falls 2.55% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Jun 24, 3:03PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $55.78 to a high of $57.07. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $56.10 on volume of 5.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MRK: 55.88 (-1.80)
Watch for Merck to Potentially Rebound After Falling 2.55% Yesterday
Comtex SmarTrend(R) - Fri Jun 24, 3:01PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $55.78 to a high of $57.07. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $56.10 on volume of 5.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MRK: 55.88 (-1.80)
Merck to Hold Second-Quarter 2016 Sales and Earnings Conference Call on July 29
BusinessWire - Fri Jun 24, 7:00AM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, will hold its second-quarter 2016 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Friday, July 29. During the call, company executives will provide an overview of Merck's performance for the quarter.
MRK: 55.88 (-1.80)
Incyte Reports Epacadostat Combination Study Initiation
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 9:59AM CDT
Incyte (INCY) reported that the first patient has been treated in a phase III epacadostat combination study for advanced or metastatic melanoma.
ANIP: 54.34 (-1.93), INCY: 76.98 (-4.68), MRK: 55.88 (-1.80), BMY: 70.61 (-2.03)
Valeritas Appoints David Lewis as Vice President of Marketing
GlobeNewswire - Thu Jun 23, 7:00AM CDT
Valeritas Holdings, Inc. (OTCQB:VLRX) announced today that David Lewis has been named Vice President of Marketing. Mr. Lewis joins the Company with extensive experience successfully building chronic therapeutic brands including several current market-leading brands in diabetes. Notably, Mr. Lewis led the launch of Januvia, one of Merck & Company's first and most successful new product launches in the U.S. diabetes market, and then went on to lead marketing for the global launch of AstraZeneca and Bristol-Myers Squibb's Forxiga for the treatment of type-2 diabetes.
MRK: 55.88 (-1.80), VLRX: (), BMY: 70.61 (-2.03)
Merck (MRK) Approaches New Upside Target of $56.77
Comtex SmarTrend(R) - Tue Jun 21, 9:09AM CDT
Shares of Merck (NYSE:MRK) have bullishly opened above the pivot of $56.29 today and have reached the first resistance level of $56.45. Investors may be interested in a cross of the next upside pivot targets of $56.77 and $57.25.
MRK: 55.88 (-1.80)
Roger Ulrich Joins Board of Remedy Pharmaceuticals
BusinessWire - Tue Jun 21, 9:00AM CDT
Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today announced that Roger Ulrich has joined the company's board of directors.
GILD: 80.47 (-2.90), PFE: 33.97 (-0.62), MRK: 55.88 (-1.80), AZN: 27.86 (-1.43)
Results of Phase 2 Study of Merck's Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem/Cilastatin Presented at ASM Microbe
BusinessWire - Mon Jun 20, 11:30AM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that a Phase 2 study of relebactam, the company's investigational beta-lactamase inhibitor, in combination with imipenem/cilastatin (an approved carbapenem antibiotic), in patients with complicated urinary tract infections, met its primary endpoint. The addition of relebactam is designed to restore activity of imipenem against certain imipenem-resistant strains of Gram-negative bacteria, including Pseudomonas aeruginosa and Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae.
MRK: 55.88 (-1.80)
Stock Market News for June 20, 2016
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 9:10AM CDT
Looming Brexit fears and Fed not hiking rates this month dragged benchmarks down on Friday, eventually finishing out the week lower
JNJ: 115.63 (-1.75), PXD: 152.92 (-7.67), V: 75.05 (-3.18), FB: 112.08 (-3.00), UNH: 137.29 (-1.90), MRK: 55.88 (-1.80), PFE: 33.97 (-0.62), EOG: 81.06 (-3.44), GOOGL: 685.20 (-29.67), CVX: 101.90 (-2.54), MSFT: 49.83 (-2.08), SLB: 76.66 (-2.93)
The Zacks Analyst Blog Highlights: Baker Hughes, LinkedIn, Microsoft, Apple and Merck
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 8:30AM CDT
The Zacks Analyst Blog Highlights: Baker Hughes, LinkedIn, Microsoft, Apple and Merck
LNKD: 190.11 (-0.34), MRK: 55.88 (-1.80), MSFT: 49.83 (-2.08), AAPL: 93.40 (-2.70), BHI: 45.22 (-1.95)
Cytochrome P450 11B2 Mitochondrial Pipeline Review, H1 2016 Featuring Angion Biomedica Corp, Merck & Co., & Novartis AG - Research and Markets
BusinessWire - Fri Jun 17, 1:01PM CDT
Research and Markets has announced the addition of the "Cytochrome P450 11B2 Mitochondrial - Pipeline Review, H1 2016" report to their offering.
MRK: 55.88 (-1.80), NVS: 77.10 (-3.57)
Research and Markets - Global Cell Expansion Market Value of USD 18.76 Billion by 2021 - Trends, Technologies & Opportunities Report 2016-2021 - Key Vendors: Merck, Miltenyi Biotec, GE Healthcare
PR Newswire - Fri Jun 17, 12:10PM CDT
Research and Markets has announced the addition of the "Cell Expansion Market by Product (Reagent, Media, Flow Cytometer, Centrifuge, Bioreactor), Cell Type (Human, Animal), Application (Regenerative Medicine & Stem Cell Research, Cancer), End user (Research Institute, Cell Bank)-Global Forecasts to 202" report to their offering.
MRK: 55.88 (-1.80)
Dow 30 Stock Roundup: Microsoft Acquires LinkedIn, Merck to Buy Afferent Pharmaceuticals
Swarup Gupta - Zacks Investment Research - Fri Jun 17, 10:06AM CDT
The Dow suffered significantly last week, weighed down by concerns about the path of rate hikes and a possible Brexit.
CI: 127.71 (-2.04), LNKD: 190.11 (-0.34), JPM: 59.60 (-4.45), UNH: 137.29 (-1.90), MRK: 55.88 (-1.80), MSFT: 49.83 (-2.08), AET: 117.66 (-3.34), AAPL: 93.40 (-2.70), CSCO: 27.75 (-1.47), BHI: 45.22 (-1.95), HUM: 182.90 (-4.41)
Cavium and Marathon Oil skid, while Kroger and Newmont rise
AP - Thu Jun 16, 3:46PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Thursday:
CAVM: 37.71 (-2.41), ED: 78.41 (+1.55), MRK: 55.88 (-1.80), NEM: 37.19 (+1.80), M: 32.08 (-1.30), MRO: 14.59 (-0.68)
Merck & Co. Inc. Shares Jump On Positive Lung Cancer Treatment Trial Results
Adam Clark - Zacks Investment Research - Thu Jun 16, 3:01PM CDT
Large pharmaceutical company Merck & Co. Inc. saw its shares jump over 2.5% and continued to climb Thursday afternoon on a positive announcement from its trial of Keytruda as the sole treatment of late-stage lung cancer.
MRK: 55.88 (-1.80)
Merck Set to Possibly Pullback After Yesterday's Rally of 2.28%
Comtex SmarTrend(R) - Thu Jun 16, 11:53AM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $56.13 to a high of $57.40. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $56.68 on volume of 12.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MRK: 55.88 (-1.80)
Look for Shares of Merck to Potentially Pullback after Yesterday's 2.28% Rise
Comtex SmarTrend(R) - Thu Jun 16, 11:51AM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $56.13 to a high of $57.40. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $56.68 on volume of 12.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MRK: 55.88 (-1.80)
Merck's KEYTRUDA(R) (pembrolizumab) Demonstrates Superior Progression-Free and Overall Survival Compared to Chemotherapy as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer
BusinessWire - Thu Jun 16, 5:45AM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the KEYNOTE-024 trial investigating the use of KEYTRUDA(R) (pembrolizumab), in patients with previously untreated advanced non-small cell lung cancer (NSCLC) whose tumors expressed high levels of PD-L1 (tumor proportion score of 50 percent or more), met its primary endpoint. In this trial, KEYTRUDA was superior compared to chemotherapy for both the primary endpoint of progression-free survival (PFS), and the secondary endpoint of overall survival (OS). Based on these results, an independent Data Monitoring Committee (DMC) has recommended that the trial be stopped, and that patients receiving chemotherapy in KEYNOTE-024 be offered the opportunity to receive KEYTRUDA.
MRK: 55.88 (-1.80)
Merck Highlights Ongoing Commitment to Fighting Infectious Diseases with More than 30 Data Presentations at ASM Microbe 2016
BusinessWire - Wed Jun 15, 7:30AM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that researchers are scheduled to provide more than 30 scientific data presentations on the company's established and investigational infectious disease medicines and vaccines at the American Society for Microbiology's ASM Microbe 2016 meeting in Boston, June 16-20.
MRK: 55.88 (-1.80)
Merck Manuals Provides Tips for Avoiding Tick-Borne Illnesses
PR Newswire - Wed Jun 15, 7:08AM CDT
As outdoor activity increases during the summertime, the risk of encountering ticks and contracting a tick-borne illness also rises. Yet ticks are difficult to spot and tick-transmitted diseases do not always manifest in obvious or immediate symptoms, making it difficult to prevent or identify potential illness.
MRK: 55.88 (-1.80)
Merck Falls 2.55% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Jun 24, 3:03PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $55.78 to a high of $57.07. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $56.10 on volume of 5.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MRK: 55.88 (-1.80)
Watch for Merck to Potentially Rebound After Falling 2.55% Yesterday
Comtex SmarTrend(R) - Fri Jun 24, 3:01PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $55.78 to a high of $57.07. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $56.10 on volume of 5.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MRK: 55.88 (-1.80)
Merck to Hold Second-Quarter 2016 Sales and Earnings Conference Call on July 29
BusinessWire - Fri Jun 24, 7:00AM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, will hold its second-quarter 2016 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Friday, July 29. During the call, company executives will provide an overview of Merck's performance for the quarter.
MRK: 55.88 (-1.80)
Incyte Reports Epacadostat Combination Study Initiation
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 9:59AM CDT
Incyte (INCY) reported that the first patient has been treated in a phase III epacadostat combination study for advanced or metastatic melanoma.
ANIP: 54.34 (-1.93), INCY: 76.98 (-4.68), MRK: 55.88 (-1.80), BMY: 70.61 (-2.03)
Valeritas Appoints David Lewis as Vice President of Marketing
GlobeNewswire - Thu Jun 23, 7:00AM CDT
Valeritas Holdings, Inc. (OTCQB:VLRX) announced today that David Lewis has been named Vice President of Marketing. Mr. Lewis joins the Company with extensive experience successfully building chronic therapeutic brands including several current market-leading brands in diabetes. Notably, Mr. Lewis led the launch of Januvia, one of Merck & Company's first and most successful new product launches in the U.S. diabetes market, and then went on to lead marketing for the global launch of AstraZeneca and Bristol-Myers Squibb's Forxiga for the treatment of type-2 diabetes.
MRK: 55.88 (-1.80), VLRX: (), BMY: 70.61 (-2.03)
Merck (MRK) Approaches New Upside Target of $56.77
Comtex SmarTrend(R) - Tue Jun 21, 9:09AM CDT
Shares of Merck (NYSE:MRK) have bullishly opened above the pivot of $56.29 today and have reached the first resistance level of $56.45. Investors may be interested in a cross of the next upside pivot targets of $56.77 and $57.25.
MRK: 55.88 (-1.80)
Roger Ulrich Joins Board of Remedy Pharmaceuticals
BusinessWire - Tue Jun 21, 9:00AM CDT
Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today announced that Roger Ulrich has joined the company's board of directors.
GILD: 80.47 (-2.90), PFE: 33.97 (-0.62), MRK: 55.88 (-1.80), AZN: 27.86 (-1.43)
Results of Phase 2 Study of Merck's Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem/Cilastatin Presented at ASM Microbe
BusinessWire - Mon Jun 20, 11:30AM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that a Phase 2 study of relebactam, the company's investigational beta-lactamase inhibitor, in combination with imipenem/cilastatin (an approved carbapenem antibiotic), in patients with complicated urinary tract infections, met its primary endpoint. The addition of relebactam is designed to restore activity of imipenem against certain imipenem-resistant strains of Gram-negative bacteria, including Pseudomonas aeruginosa and Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae.
MRK: 55.88 (-1.80)
Stock Market News for June 20, 2016
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 9:10AM CDT
Looming Brexit fears and Fed not hiking rates this month dragged benchmarks down on Friday, eventually finishing out the week lower
JNJ: 115.63 (-1.75), PXD: 152.92 (-7.67), V: 75.05 (-3.18), FB: 112.08 (-3.00), UNH: 137.29 (-1.90), MRK: 55.88 (-1.80), PFE: 33.97 (-0.62), EOG: 81.06 (-3.44), GOOGL: 685.20 (-29.67), CVX: 101.90 (-2.54), MSFT: 49.83 (-2.08), SLB: 76.66 (-2.93)
The Zacks Analyst Blog Highlights: Baker Hughes, LinkedIn, Microsoft, Apple and Merck
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 8:30AM CDT
The Zacks Analyst Blog Highlights: Baker Hughes, LinkedIn, Microsoft, Apple and Merck
LNKD: 190.11 (-0.34), MRK: 55.88 (-1.80), MSFT: 49.83 (-2.08), AAPL: 93.40 (-2.70), BHI: 45.22 (-1.95)
Cytochrome P450 11B2 Mitochondrial Pipeline Review, H1 2016 Featuring Angion Biomedica Corp, Merck & Co., & Novartis AG - Research and Markets
BusinessWire - Fri Jun 17, 1:01PM CDT
Research and Markets has announced the addition of the "Cytochrome P450 11B2 Mitochondrial - Pipeline Review, H1 2016" report to their offering.
MRK: 55.88 (-1.80), NVS: 77.10 (-3.57)
Research and Markets - Global Cell Expansion Market Value of USD 18.76 Billion by 2021 - Trends, Technologies & Opportunities Report 2016-2021 - Key Vendors: Merck, Miltenyi Biotec, GE Healthcare
PR Newswire - Fri Jun 17, 12:10PM CDT
Research and Markets has announced the addition of the "Cell Expansion Market by Product (Reagent, Media, Flow Cytometer, Centrifuge, Bioreactor), Cell Type (Human, Animal), Application (Regenerative Medicine & Stem Cell Research, Cancer), End user (Research Institute, Cell Bank)-Global Forecasts to 202" report to their offering.
MRK: 55.88 (-1.80)
Dow 30 Stock Roundup: Microsoft Acquires LinkedIn, Merck to Buy Afferent Pharmaceuticals
Swarup Gupta - Zacks Investment Research - Fri Jun 17, 10:06AM CDT
The Dow suffered significantly last week, weighed down by concerns about the path of rate hikes and a possible Brexit.
CI: 127.71 (-2.04), LNKD: 190.11 (-0.34), JPM: 59.60 (-4.45), UNH: 137.29 (-1.90), MRK: 55.88 (-1.80), MSFT: 49.83 (-2.08), AET: 117.66 (-3.34), AAPL: 93.40 (-2.70), CSCO: 27.75 (-1.47), BHI: 45.22 (-1.95), HUM: 182.90 (-4.41)
Cavium and Marathon Oil skid, while Kroger and Newmont rise
AP - Thu Jun 16, 3:46PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Thursday:
CAVM: 37.71 (-2.41), ED: 78.41 (+1.55), MRK: 55.88 (-1.80), NEM: 37.19 (+1.80), M: 32.08 (-1.30), MRO: 14.59 (-0.68)
Merck & Co. Inc. Shares Jump On Positive Lung Cancer Treatment Trial Results
Adam Clark - Zacks Investment Research - Thu Jun 16, 3:01PM CDT
Large pharmaceutical company Merck & Co. Inc. saw its shares jump over 2.5% and continued to climb Thursday afternoon on a positive announcement from its trial of Keytruda as the sole treatment of late-stage lung cancer.
MRK: 55.88 (-1.80)
Merck Set to Possibly Pullback After Yesterday's Rally of 2.28%
Comtex SmarTrend(R) - Thu Jun 16, 11:53AM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $56.13 to a high of $57.40. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $56.68 on volume of 12.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MRK: 55.88 (-1.80)
Look for Shares of Merck to Potentially Pullback after Yesterday's 2.28% Rise
Comtex SmarTrend(R) - Thu Jun 16, 11:51AM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $56.13 to a high of $57.40. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $56.68 on volume of 12.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MRK: 55.88 (-1.80)
Merck's KEYTRUDA(R) (pembrolizumab) Demonstrates Superior Progression-Free and Overall Survival Compared to Chemotherapy as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer
BusinessWire - Thu Jun 16, 5:45AM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the KEYNOTE-024 trial investigating the use of KEYTRUDA(R) (pembrolizumab), in patients with previously untreated advanced non-small cell lung cancer (NSCLC) whose tumors expressed high levels of PD-L1 (tumor proportion score of 50 percent or more), met its primary endpoint. In this trial, KEYTRUDA was superior compared to chemotherapy for both the primary endpoint of progression-free survival (PFS), and the secondary endpoint of overall survival (OS). Based on these results, an independent Data Monitoring Committee (DMC) has recommended that the trial be stopped, and that patients receiving chemotherapy in KEYNOTE-024 be offered the opportunity to receive KEYTRUDA.
MRK: 55.88 (-1.80)
Merck Highlights Ongoing Commitment to Fighting Infectious Diseases with More than 30 Data Presentations at ASM Microbe 2016
BusinessWire - Wed Jun 15, 7:30AM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that researchers are scheduled to provide more than 30 scientific data presentations on the company's established and investigational infectious disease medicines and vaccines at the American Society for Microbiology's ASM Microbe 2016 meeting in Boston, June 16-20.
MRK: 55.88 (-1.80)
Merck Manuals Provides Tips for Avoiding Tick-Borne Illnesses
PR Newswire - Wed Jun 15, 7:08AM CDT
As outdoor activity increases during the summertime, the risk of encountering ticks and contracting a tick-borne illness also rises. Yet ticks are difficult to spot and tick-transmitted diseases do not always manifest in obvious or immediate symptoms, making it difficult to prevent or identify potential illness.
MRK: 55.88 (-1.80)
